Expression patterns of carbonic anhydrase IX and immune response biomarkers in pediatric gliomas and glioneuronal tumors
Clinical Scorecard: Patterns of Carbonic Anhydrase IX and Immune Biomarkers in Pediatric Gliomas and Glioneuronal Tumors
At a Glance
| Category | Detail |
|---|
| Condition | Pediatric CNS tumors |
| Key Mechanisms | Hypoxia-related molecular targets, specifically Carbonic Anhydrase IX (CAIX), which regulates intracellular pH and supports tumor invasion. |
| Target Population | Pediatric patients aged 0–17 years diagnosed with CNS tumors. |
| Care Setting | Neuro-oncology clinical practice. |
Key Highlights
- CAIX expression is associated with high-grade tumors and worse prognosis in pediatric CNS tumors.
- Pediatric tumors exhibit low tumor mutational burden and reduced immunogenicity.
- The study evaluates CAIX and immune biomarker expression in pediatric low-grade gliomas, high-grade gliomas, and glioneuronal tumors.
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on histology, immunohistochemistry, and molecular classification.
Management
- Consider novel therapeutic strategies targeting CAIX and immune biomarkers.
Monitoring & Follow-up
- Event-free survival (EFS) and overall survival (OS) should be monitored post-diagnosis.
Risks
- Hypoxia may promote tumor progression and treatment resistance.
Patient & Prescribing Data
Patients diagnosed with gliomas and glioneuronal tumors between January 2000 and February 2022.
Novel therapeutic approaches include anti-CAIX-directed antibodies and small-molecule inhibitors.
Clinical Best Practices
- Utilize comprehensive immune biomarker panels for characterizing tumor behavior.
- Employ the Heidelberg CNS Tumor Methylation Classifier for accurate diagnosis.
Related Resources & Content
